Drug Trial Radar · NCT07537881
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
326
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Dec 30, 2029
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Conditions
- Solid Tumors
Interventions
RC288 For InjectionDrug
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.
RC288 For InjectionDrug
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT)Time frame: 24 months
- Incidence and severity of adverse events/serious adverse events (graded according to NCI CTCAE v6.0)Time frame: 24 months
- Determine RP2D of RC288Time frame: 24 months
- MTD and/or MADTime frame: 24 months
- Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteria and PCWG3 criteriaTime frame: 24 months
- Non-Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteriaTime frame: 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Hunan, Changsha, China · Not yet recruiting
Sichuan Cancer Hospital & Institute
Sichuan, Chengdu, China · Not yet recruiting
Fujian Cancer Hospital
Fujian, Fuzhou, China · Not yet recruiting
Fujian Medical University Union Hospital
Fujian, Fuzhou, China · Not yet recruiting
Sun Yat sen University Cancer Center
Guangdong, Guangzhou, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guizhou, Guiyang, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Heilongjiang, Haerbin, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Cancer Hospital of Shandong First Medical University Cancer Hospital
Shandong, Jinan, China · Not yet recruiting
Shanxi Cancer Hospital
Shandong, Jinan, China · Recruiting
Shanxi Cancer Hospital
Shanxi, Shanxi, China · Recruiting
Taizhou Hospital of Zhejiang Province
Zhejiang, Taizhou, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Zhejiang, Wenzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.